Equities
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Fresenius Medical Care AG, formerly Fresenius Medical Care AG & Co. KGaA is a Germany-based kidney dialysis institute. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD) and offers other extracorporeal therapies, as well as other healthcare services. It has two operating segments such as care delivery segment which consolidates the global health care services business and care enablement segment includes research and development (R&D), manufacturing, supply chain, and commercial operations. It develops and manufactures health care products, which includes dialysis and non-dialysis products. Such as hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. It owns, operates, or manages dialysis clinics sells products to other dialysis providers.

  • Revenue in EUR (TTM)19.49bn
  • Net income in EUR618.18m
  • Incorporated2006
  • Employees112.04k
More ▼

Institutional shareholders

21.55%Per cent of shares held by top holders
HolderShares% Held
Dodge & Coxas of 03 Jul 202514.60m4.98%
Artisan Partners LPas of 30 Apr 20258.85m3.02%
Harris Associates LPas of 14 Apr 20258.75m2.98%
The Vanguard Group, Inc.as of 02 Jul 20257.88m2.69%
Pzena Investment Management LLCas of 30 Jun 20255.84m1.99%
DWS Investment GmbHas of 03 Jul 20255.29m1.80%
BlackRock Fund Advisorsas of 03 Jul 20254.56m1.56%
Geode Capital Management LLCas of 10 Jul 20252.62m0.90%
BlackRock Advisors (UK) Ltd.as of 04 Jul 20252.46m0.84%
Fiduciary Management, Inc.as of 31 Mar 20252.38m0.81%
More ▼
Data from 31 Mar 2025 - 31 Mar 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.